Kazia Therapeutics (KZIA) Fundamental Analysis: Revenue, Earnings & Valuation

2.12 / 10

Underperform

Fundamentally, KZIA scores poorly (2.1/10) and is rated Underperform. Revenue fell 23.7% YoY, while gross margin is high at 100%. Inventory turnover is modest, fixed‑asset turnover strong, but cost‑of‑sales ratio and tax burden drag performance, yielding a low composite score of 2.12.

Analysis Checks(5/6)

Total operating revenue (YoY growth rate %)

Value-23.75

Score2/3

Weight27.27%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score2/3

Weight31.77%

1M Return-1.21%

Gross profit margin (%)

Value100.00

Score2/3

Weight-51.52%

1M Return1.69%

Income tax / Total profit (%)

Value7.78

Score1/3

Weight13.03%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight-29.11%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight108.56%

1M Return-4.42%

Is KZIA fundamentally strong?

KZIA scores 2.12/10 on fundamentals and holds a Premium valuation at present. Backed by its -65.78% ROE, -1118.75% net margin, -5.29 P/E ratio, 2.65 P/B ratio, and 74.05% earnings growth, these metrics solidify its Underperform investment rating.